Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

View Slides

Literature Highlights - November 2024

more…

Keywords:

systemic lupus erythematosus, randomized clinical trial, belimumab, disease activity, patient-reported outcomes, disease trajectories, Efficacy, Iberdomide, Phase 2, Safety, CLE,, SLE, Type 2 diabetes, Cardiovascular, Renal, SGLT2i

August 2024

Publication thumbnail: Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares

View Slides

Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares

J Transl Autoimmun 2024;9:100244 DOI 10.1016/j.jtauto.2024.100244

Renaudineau, et al. show that the urinary sCD163/creatinurea ratio is a parameter than can be used in addition to anti-dsDNA antibodies, anti-C1q antibodies, C3 complement fraction, the protein excretion to creatinine ratio and the estimated glomerular filtration rate.

more…

Keywords:

Biomarkers; End stage kidney disease; Flare; Remission; Urinary soluble CD163; lupus nephritis.

July 2022

Publication thumbnail: Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial

View Slides

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial

Jourde-Chiche N

Costedoat-Chalumeau N

Daugas E; WIN-Lupus study group.

Jourde-Chiche N, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222435.

Non-inferiority of maintenance immunosuppressive therapy (IST) discontinuation after 2‒3 years was not demonstrated for renal relapse, in proliferative lupus nephritis (LN).

more…